Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276395 | 0.89 | KMT2A (0.64) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL8590837 | 0.89 | KMT2A (0.64) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL15259117 | 0.88 | KMT2A (0.62) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL15947382 | 0.79 | KMT2A (0.77) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL8404658 | 0.79 | KMT2A (0.81) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL14395933 | 0.78 | KMT2A (0.67) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL14853589 | 0.77 | KMT2A (0.73) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL8591612 | 0.77 | KMT2A (0.65) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| SCHEMBL276856 | 0.77 | KMT2A (0.68) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 | |
| Bromide SCHEMBL11867443 | 0.76 | KMT2A (0.71) | HPGDSMN1; SMN2KMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | HPGD 750/4885SMN1; SMN2 555/4885KMT2A 1024/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | HPGD 750/4885SMN1; SMN2 555/4885KMT2A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.